Categories: DNANews

CellarisBio Announces “CHALLENGING TARGET AWARD” to Promote Innovation in Drug Discovery

SAN DIEGO, Dec. 16, 2024 /PRNewswire/ — CellarisBio breaks ground with an announcement of “Challenging Target Award” to foster innovation in the space of challenging therapeutic targets. The award is designed to de-risk & accelerate first-in-class and best-in-class drug discovery programs. It will provide the awardee with exclusive access to CellarisBio’s MICRO-TAG cell target engagement platform. The platform enables:

  • Drug discovery using DNA-Encoded Libraries (DELs),
  • Hit-to-lead optimization,
  • Real-time analysis for mechanism-of-action studies.

The award will launch on January 15th, 2025, at https://cellarisbio.com/award and the winner will be announced on April 15th, 2025.

Our mission is to expand the druggable proteome for discovery of precision therapeutics. We are particularly keen on challenging drug targets, proteins that have been known as undruggable. We tackle them within the native environment of the cell.” stated Elmar Nurmemmedov, cofounder and CEO at CellarisBio. “There are more than 9000 undiscovered therapies that are locked behind challenging drug targets. We pledge to work closely with ambitious biotechs to unlock life-saving therapies of the future.” Elmar added.

“In the recent years, we have witnessed an evolution of drug discovery technologies and therapeutic modalities. It is now becoming increasingly imperative to use live cells as filters to de-risk and accelerate therapeutic findings. Demonstration of direct drug target engagement within the cellular environment is indispensable for drug pharmacology. The “Challenging Target Award” is agnostic to the target family, disease area and how drug candidates were discovered.” said Ivan Babic, cofounder at CellarisBio.

Watch the official CellarisBio trailer here: Youtube

Award link: CellarisBio

About CellarisBio
CellarisBio is a techbio company, developing the next-gen cell target engagement technology, delivered as MICRO-TAG™ platform. Based at Biovista labs in San Diego, CellarisBio, the company capitalizes on several patents protecting the technology. CellarisBio has recently fostered multiple partnerships with companies around the world.

Contact:
hi@cellarisbio.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cellarisbio-announces-challenging-target-award-to-promote-innovation-in-drug-discovery-302332222.html

SOURCE CellarisBio

Staff

Recent Posts

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…

3 hours ago

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

6 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

6 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

6 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

6 hours ago

RxAnte Announces Strategic Growth Investment from Primus Capital

PORTLAND, Maine, Jan. 12, 2026 /PRNewswire/ -- RxAnte, the leading provider of analytics, software, and…

6 hours ago